

# Eric S Lipp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4489200/publications.pdf>

Version: 2024-02-01

115  
papers

11,881  
citations

159585

30  
h-index

64796

79  
g-index

116  
all docs

116  
docs citations

116  
times ranked

19690  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Availability and Role of Clinical Pharmacists in Ambulatory Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2022, 9, 18-23.   | 1.6  | 0         |
| 2  | Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. <i>Supportive Care in Cancer</i> , 2022, 30, 3463-3471.  | 2.2  | 3         |
| 3  | A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015. | 1.6  | 5         |
| 4  | Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.  | 12.8 | 77        |
| 5  | Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 299-309.   | 1.6  | 5         |
| 6  | Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.  | 2.8  | 0         |
| 7  | An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9521-9521.  | 1.6  | 0         |
| 8  | Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. <i>CNS Oncology</i> , 2021, 10, CNS77.  | 3.0  | 3         |
| 9  | QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS. <i>Neuro-Oncology</i> , 2021, 23, vi184-vi185.   | 1.2  | 0         |
| 10 | QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE. <i>Neuro-Oncology</i> , 2021, 23, vi189-vi189.   | 1.2  | 0         |
| 11 | BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM. <i>Neuro-Oncology</i> , 2021, 23, vi14-vi15.  | 1.2  | 0         |
| 12 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.           | 2.2  | 9         |
| 13 | Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.   | 7.7  | 36        |
| 14 | The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. <i>Clinical Cancer Research</i> , 2020, 26, 5809-5813.  | 7.0  | 44        |
| 15 | IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii365-iii365.  | 1.2  | 0         |
| 16 | Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020, 147, 477-483.   | 2.9  | 4         |
| 17 | CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii37-ii37.   | 1.2  | 4         |
| 18 | Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2566-2566.  | 1.6  | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | NCOG-38. CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS. <i>Neuro-Oncology</i> , 2020, 22, ii137-ii137.   | 1.2 | 0         |
| 20 | QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS. <i>Neuro-Oncology</i> , 2020, 22, ii179-ii179.   | 1.2 | 0         |
| 21 | NCOG-23. PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii134-ii134.  | 1.2 | 0         |
| 22 | COVID-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING. <i>Neuro-Oncology</i> , 2020, 22, ii26-ii26.  | 1.2 | 0         |
| 23 | QOLP-05. OLANZAPINE FOR REFRACTORY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii175-ii175.  | 1.2 | 0         |
| 24 | CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2020, 22, ii38-ii38.  | 1.2 | 3         |
| 25 | Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.  | 1.7 | 5         |
| 26 | First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E106. | 0.8 | 3         |
| 27 | Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. <i>Health Science Reports</i> , 2019, 2, e114.   | 1.5 | 10        |
| 28 | ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019, 21, vi6-vi6.   | 1.2 | 1         |
| 29 | ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi8-vi8.   | 1.2 | 0         |
| 30 | QOLP-18. A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi201.   | 1.2 | 2         |
| 31 | QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.  | 1.2 | 1         |
| 32 | Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz036.   | 0.7 | 4         |
| 33 | HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS. <i>Neuro-Oncology</i> , 2019, 21, vi116-vi116.   | 1.2 | 0         |
| 34 | INNV-18. THE AVAILABILITY AND ROLE OF CLINICAL PHARMACISTS IN THE AMBULATORY NEURO-ONCOLOGY SETTING: AN INTERNATIONAL SURVEY. <i>Neuro-Oncology</i> , 2019, 21, vi134-vi134.  | 1.2 | 0         |
| 35 | MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.  | 1.7 | 8         |
| 36 | Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2060-2060.   | 1.6 | 2         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology, 2019, 37, e13526-e13526.  | 1.6  | 8         |
| 38 | Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. Oncologist, 2018, 23, 889-e98.  | 3.7  | 26        |
| 39 | A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.   | 28.9 | 228       |
| 40 | Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.  | 6.4  | 333       |
| 41 | Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.   | 6.4  | 245       |
| 42 | Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.  | 6.4  | 205       |
| 43 | Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist, 2018, 23, 157-e21.  | 3.7  | 44        |
| 44 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Journal of Neuro-Oncology, 2018, 137, 349-356.  | 2.9  | 49        |
| 45 | Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.   | 6.2  | 284       |
| 46 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.   | 16.8 | 750       |
| 47 | QOLP-17. REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS. Neuro-Oncology, 2018, 20, vi218-vi218.  | 1.2  | 1         |
| 48 | GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi112-vi112.   | 1.2  | 0         |
| 49 | HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS. Neuro-Oncology, 2018, 20, vi117-vi117.                  | 1.2  | 0         |
| 50 | RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS. Neuro-Oncology, 2018, 20, vi239-vi239.   | 1.2  | 0         |
| 51 | ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi17-vi17. | 1.2  | 1         |
| 52 | QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS. Neuro-Oncology, 2018, 20, vi217-vi217.  | 1.2  | 0         |
| 53 | ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2018, 20, vi9-vi9.      | 1.2  | 2         |
| 54 | ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIP0) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. Neuro-Oncology, 2018, 20, vi7-vi7.   | 1.2  | 0         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442.  | 1.5  | 5         |
| 56 | Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 472-485.   | 1.5  | 7         |
| 57 | GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi103.  | 1.2  | 0         |
| 58 | A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$ Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.  | 6.2  | 134       |
| 59 | Adjunctive perampanel for glioma-associated epilepsy. <i>Epilepsy &amp; Behavior Case Reports</i> , 2018, 10, 114-117.  | 1.5  | 26        |
| 60 | HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018, 20, i93-i93.   | 1.2  | 2         |
| 61 | The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.  | 12.8 | 124       |
| 62 | Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.   | 7.7  | 86        |
| 63 | Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1697-1704.   | 2.5  | 44        |
| 64 | A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. <i>Journal of Neuro-Oncology</i> , 2017, 134, 363-369.             | 2.9  | 18        |
| 65 | Morphological and molecular features of astroblastoma, including <i>BRAFV600E</i> mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. <i>Neuro-Oncology</i> , 2017, 19, 31-42. | 1.2  | 45        |
| 66 | PALL-10. INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2017, 19, vi170-vi170.   | 1.2  | 0         |
| 67 | PALL-02. PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi168-vi168.   | 1.2  | 0         |
| 68 | QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2017, 19, vi206-vi206.                                       | 1.2  | 0         |
| 69 | QLIF-05. A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi202-vi202.   | 1.2  | 1         |
| 70 | QLIF-34. PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW GRADE GLIOMAS (LGG). <i>Neuro-Oncology</i> , 2017, 19, vi208-vi209.   | 1.2  | 0         |
| 71 | ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2017, 19, vi14-vi14.   | 1.2  | 1         |
| 72 | RARE-36. PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. <i>Neuro-Oncology</i> , 2017, 19, vi217-vi217.  | 1.2  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2017, 35, e13532-e13532.                     | 1.6  | 2         |
| 74 | Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. Journal of Clinical Oncology, 2017, 35, e13533-e13533.                                    | 1.6  | 0         |
| 75 | Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2017, 35, e21636-e21636.  | 1.6  | 0         |
| 76 | QLIF-20. A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS. Neuro-Oncology, 2016, 18, vi160-vi160.   | 1.2  | 0         |
| 77 | ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2016, 18, vi21-vi22.   | 1.2  | 1         |
| 78 | NCOG-12. NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS. Neuro-Oncology, 2016, 18, vi122-vi122.   | 1.2  | 0         |
| 79 | Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.   | 1.6  | 160       |
| 80 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.  | 10.7 | 274       |
| 81 | Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. Journal of Clinical Oncology, 2016, 34, 2061-2061. | 1.6  | 17        |
| 82 | Baseline cognitive function to predict survival in patients with glioblastoma.. Journal of Clinical Oncology, 2016, 34, 10125-10125.   | 1.6  | 1         |
| 83 | QOL-19 PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN. Neuro-Oncology, 2015, 17, v192.1-v192.   | 1.2  | 0         |
| 84 | QOL-20 LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY. Neuro-Oncology, 2015, 17, v192.2-v192.  | 1.2  | 0         |
| 85 | ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2015, 17, v1.1-v1.   | 1.2  | 1         |
| 86 | QOL-21 DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. Neuro-Oncology, 2015, 17, v192.3-v192.   | 1.2  | 0         |
| 87 | Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. Oncologist, 2015, 20, 727-728.  | 3.7  | 32        |
| 88 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.   | 27.0 | 2,582     |
| 89 | Consultative Issues in Surgical Neuropathology. American Journal of Clinical Pathology, 2015, 143, 807-811.  | 0.7  | 3         |
| 90 | Prognostic marker analysis in pediatric intracranial ependymomas. Journal of Neuro-Oncology, 2015, 122, 255-261.   | 2.9  | 10        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Proteomic profiling of patientâ€derived glioblastoma xenografts identifies a subset with activated <sc>EGFR</sc>: implications for drug development. Journal of Neurochemistry, 2015, 133, 730-738.                | 3.9  | 11        |
| 92  | Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2034-2034.   | 1.6  | 4         |
| 93  | Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. Journal of Clinical Oncology, 2015, 33, 2068-2068.   | 1.6  | 9         |
| 94  | Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. Journal of Clinical Oncology, 2015, 33, 2067-2067.         | 1.6  | 0         |
| 95  | Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2015, 33, e13004-e13004. | 1.6  | 0         |
| 96  | Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. Journal of Clinical Oncology, 2015, 33, 9553-9553.   | 1.6  | 1         |
| 97  | Secondary cancers in long-term survivors of primary glioblastoma.. Journal of Clinical Oncology, 2015, 33, e20616-e20616.  | 1.6  | 0         |
| 98  | The genetic landscape of anaplastic astrocytoma. Oncotarget, 2014, 5, 1452-1457.   | 1.8  | 69        |
| 99  | Mutations in <i>IDH1</i>, <i>IDH2</i>, and in the <i>TERT</i> promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 2014, 5, 1515-1525.  | 1.8  | 237       |
| 100 | Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. Journal of Clinical Oncology, 2014, 32, 2082-2082.                | 1.6  | 0         |
| 101 | The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.   | 28.9 | 3,979     |
| 102 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.  | 10.7 | 307       |
| 103 | Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine, 2013, 2, 185-195.   | 2.8  | 36        |
| 104 | Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer, 2012, 107, 1481-1487.  | 6.4  | 83        |
| 105 | Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology, 2012, 39, 23-34.      | 0.6  | 30        |
| 106 | Frequent <i>ATRX</i>, <i>CIC</i>, <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.   | 1.8  | 532       |
| 107 | Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent lowâ€grade glioma. Cancer, 2012, 118, 4759-4767.  | 4.1  | 26        |
| 108 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology, 2012, 106, 409-415.  | 2.9  | 78        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neuro-Oncology, 2012, 107, 213-221.  | 2.9 | 24        |
| 110 | Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.. Journal of Clinical Oncology, 2012, 30, 2027-2027.                                   | 1.6 | 1         |
| 111 | Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2012, 30, 2074-2074. | 1.6 | 2         |
| 112 | Association between body mass index and mortality in patients with glioblastoma multiforme. Cancer Causes and Control, 2010, 21, 2195-2201.   | 1.8 | 24        |
| 113 | MRP3: a molecular target for human glioblastoma multiforme immunotherapy.. BMC Cancer, 2010, 10, 468.   | 2.6 | 44        |
| 114 | Family Appraisal of Caregiving in a Brain Cancer Model. Journal of Hospice and Palliative Nursing, 2009, 11, 60-66.   | 0.9 | 10        |
| 115 | Distress persists in long-term brain tumor survivors with glioblastoma multiforme. Journal of Cancer Survivorship, 2008, 2, 269-274.  | 2.9 | 26        |